Cardiology

17-32 of 306

Rethinking Thromboembolic Risk in ATTR-CM Care
Rethinking Thromboembolic Risk in ATTR-CM Care
Heart Matters
Rethinking Thromboembolic Risk in ATTR-CM Care
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Heart Matters
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Reframing Palliative Care in PAH: Early Integration to Improve Outcomes
Reframing Palliative Care in PAH: Early Integration to Improve Outcomes
Clinician's Roundtable
Reframing Palliative Care in PAH: Early Integration to Improve Outcomes
Targeting Macrophages in Pulmonary Arterial Hypertension
Targeting Macrophages in Pulmonary Arterial Hypertension
Clinician's Roundtable
Targeting Macrophages in Pulmonary Arterial Hypertension
Fatty Acid Profiles May Be Linked to PAH Risk
Fatty Acid Profiles May Be Linked to PAH Risk
AudioAbstracts
Fatty Acid Profiles May Be Linked to PAH Risk
- Ryan Quigley
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
- Florian Rader, MD
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cardiology
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Joseph Rossano, MD
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
- Joseph Rossano, MD
Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Heart Matters
Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Rebalancing Amyloid in ATTR-CM: Emerging Therapeutic Insights
Rebalancing Amyloid in ATTR-CM: Emerging Therapeutic Insights
AudioAbstracts
Rebalancing Amyloid in ATTR-CM: Emerging Therapeutic Insights
- Hallie Blevins, PhD
AI-Driven Advances in ATTR-CM Care
AI-Driven Advances in ATTR-CM Care
Heart Matters
AI-Driven Advances in ATTR-CM Care
- Frederick Ruberg, MD
Disease-Modifying Advances in ATTR-CM Management
Disease-Modifying Advances in ATTR-CM Management
Heart Matters
Disease-Modifying Advances in ATTR-CM Management
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
AudioAbstracts
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
- Ryan Quigley
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
CME/CE
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
0.25 credits
- Maria Pabon, MD
- Robert J. Mentz, MD, FHFSA, FACC
0.25 credits
Hidden HFpEF in Atrial Fibrillation: A Missed Diagnosis with Real Consequences
Hidden HFpEF in Atrial Fibrillation: A Missed Diagnosis with Real Consequences
Heart Matters
Hidden HFpEF in Atrial Fibrillation: A Missed Diagnosis with Real Consequences
Plasma Biomarkers Associated with HF Hospitalization in Atrial Fibrillation
Plasma Biomarkers Associated with HF Hospitalization in Atrial Fibrillation
Heart Matters
Plasma Biomarkers Associated with HF Hospitalization in Atrial Fibrillation

2/7

17-32 of 306

Title

Welcome to Global Cardiology Academy

Welcome to Global
Cardiology Academy